Pα+ Psychedelic Bulletin #155: MAPS Invests in Numinus, Hopes to Offer Experiential Training for MDMA Therapists

MAPS Invests in Numinus, Hopes to Offer Experiential Training for MDMA Therapists

Last Thursday, Numinus Wellness announced a $6m public offering led by Integrated.vc. Perhaps most curiously, however, was the prominent mention that the nonprofit Multidisciplinary Association for Psychedelic Studies (MAPS) would be participating in the round.

While Integrated has invested in several psychedelics firms including drug developers Transcend Therapeutics, Small Pharma (recently acquired by Cybin), and Beckley Psytech (which recently sold a chunk of equity to atai Life Sciences), MAPS has yet to delve into the investing realm¹, aside from funding its own drug development company Lykos Therapeutics (fka MAPS PBC).

According to the term sheet (see also the prospectus), fifty million units were sold for 12 cents a piece, entitling the purchaser to a common share in the company plus a warrant with a strike price of $0.18 for two years. For reference, shares in the company closed the 2023 calendar year trading at 11 cents, before reaching a local high of 20 cents in early January...